COMMUNIQUÉS West-GlobeNewswire

Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation
04/03/2026
LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare Providers HINGHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), [...]
ICAN Poll: Overwhelming Majority of Respondents Oppose Glyphosate Stockpiling, Reject Manufacturer Immunity
04/03/2026
New public opinion data from 2,569 respondents reveals near-unanimous opposition to key provisions of the administration’s glyphosate executive order AUSTIN, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- The Informed [...]
Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/03/2026
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that it granted equity awards on March 2, [...]
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
04/03/2026
Ramat Gan, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the [...]
Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration
04/03/2026
- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes - - Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker [...]
Transactions in connection with share buy-back program
04/03/2026
Company announcement no. 3 – 26 4 March 2026 NTG Nordic Transport Group A/S launches share buy-back programme The Board of Directors of NTG has decided to launch a share buy-back programme in accordance with the [...]
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
04/03/2026
The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial Vancouver, Canada, March 04, 2026 (GLOBE NEWSWIRE) -- [...]
Ardelyx to Participate in Upcoming Investor Conferences
04/03/2026
WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical [...]
Landmark Data Validate BrainsWay’s SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment
04/03/2026
World’s only FDA-cleared Deep TMS™ accelerated treatment reduces the acute phase of treatment by 70% BURLINGTON, Mass. and JERUSALEM, March 04, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) unveiled [...]
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
04/03/2026
Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-Metastatic Solid [...]
Boundless Bio to Participate in the Leerink Global Healthcare Conference
04/03/2026
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with [...]
Clover Health Moves from Pledge to Production, Becomes The First Payer Live on a CMS Aligned Network
04/03/2026
Clover Health's early adoption of real-time patient access to claims data on a CMS Aligned Network is made possible by underlying infrastructure powered by Counterpart Health. WILMINGTON, Del., March 04, 2026 (GLOBE [...]
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
04/03/2026
PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced [...]
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
04/03/2026
OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead [...]
Glucose Health Expands Retail Distribution to 2,500+ Stores, Launches National Advertising Campaign
04/03/2026
BENTONVILLE, Ark., March 04, 2026 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), a consumer-health company specializing in soluble-fiber nutrition products that support healthy glucose metabolism and metabolic [...]
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
04/03/2026
VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class [...]
From Pain to Prevention: How Dubai’s Urologist is Saving Kidneys and Lifestyles
04/03/2026
Dr. Kamalesh, Urologist in Dubai, Shares Essential Tips for Preventing Kidney Stones in the UAE Climate DUBAI, United Arab Emirates, March 04, 2026 (GLOBE NEWSWIRE) -- As temperatures remain a focal point for residents [...]
New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors
04/03/2026
ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis, demonstrating that 88% of participants prefer EUR neffy ® —the first and [...]
Philips unveils Rembra CT at ECR 2026, setting a new benchmark for speed and patient access designed to support diagnostic confidence for acute and high-demand imaging environments
04/03/2026
March 4, 2026 CE Marked and 510(k) pending, Rembra’s advanced image reconstruction technology delivers up to 106 images per second [1] and a high throughput of up to 270 patients per day [2] to support faster diagnosis [...]

Pages